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ABSTRACT 
 
According to the World Health Organization (WHO), hypertension is a major risk 
factor for cardiovascular disease (CVD), renal impairment, peripheral vascular disease, 
and blindness.  In Panama, a recent study estimated the prevalence of hypertension at 
38.5% in the two main provinces of the country, with a rate of uncontrolled hypertension 
of 47.2%. The aims of this study were to assess the feasibility of the study design and to 
describe the characteristics of the hypertensive population and the physician’s adherence 
to Panamanian antihypertensive protocols and their relationship with uncontrolled 
hypertension. 
 This is a cross-sectional study of adult hypertensive patients attending a primary 
healthcare facility in Panama City. Clinical charts from eligible participants were 
examined to describe the demographic and clinical characteristics related to uncontrolled 
hypertension and the use of antihypertensive protocols by medical doctors.  Descriptive 
and central tendency statistics were used to characterize the study population.  Bivariate 
relationships between demographic and clinical characteristics, and uncontrolled 
hypertension were explored using specific test for no association.  Logistic regression 
modeling was used to examine the association between physician’s adherence to 
antihypertensive protocols and the presence of uncontrolled hypertension. 
 In this study the mean age was 56.7 years (±13.6); 58.1% of participants were 
females; 71.3% of participants had body mass index >25.0kg/m2; and 53.0% of 
	   v	  
participants had stage 2 hypertension. Uncontrolled hypertension was present in 66.7% of 
the study sample. 82.9% of participants had one or more comorbidities. The medical 
doctors were compliant with antihypertensive protocols in 43.6% of participants, 
primarily due to lower compliance with lifestyle modification recommendations. In the 
multivariate analysis, a significant interaction was found with age, suggesting that age is 
a potential effect modifier. 
The rate of uncontrolled hypertension was high among this study population. 
Nearly half of the attending physicians did not follow the recommendations given by 
current antihypertensive protocols. Further research is necessary to explore the 
relationships between subject characteristics, such as age, number of comorbidities, and 
the presence of diabetes mellitus with uncontrolled hypertension.
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CHAPTER ONE: UNCONTROLLED HYPERTENSION AND ASSOCIATED 
RISK FACTORS 
 
Hypertension Epidemiology 
 
Hypertension (High Blood Pressure, HBP) is defined as a systolic blood pressure 
≥140 mmHg and/or a diastolic blood pressure ≥90 mm Hg, the use of antihypertensive 
medication, or being told at least twice by a physician or other health professional that 
one has HBP (Roger et al., 2012). 
 According to the World Health Organization (WHO), hypertension is a major risk 
factor for cardiovascular disease (CVD, excluding congenital CVD) as well as renal 
impairment, peripheral vascular disease, and blindness. Hypertension is estimated to 
cause 7.5 million deaths worldwide annually, about 12.8% of the total deaths (Mendis, 
Puska, & Norrving, 2011). In the same report, WHO estimates the prevalence of 
hypertension in high-income countries as 35% for both genders, while in low, lower-
middle and upper-middle income countries the prevalence is around 40%. Hypertension 
prevalence estimates from a study in seven Latin-American cities range from 13% to 
29%, with an overall prevalence of 18% (Schargrodsky et al., 2008). However, in a 
recent study developed by the WHO in six middle-income countries around the world 
(including a Latin American country), the prevalence of hypertension was 37% (Basu & 
Millett, 2013). 
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In Panama, a study estimated the prevalence of hypertension at 38.5% in the two 
main provinces of the country (McDonald et al., 2012). In 2009, according to the 
Ministry of Health of Panama, primary hypertension (under the codes of the Tenth 
Edition of the International Classification of Diseases; World Health Organization 
[WHO], 2010) was the fourth reason for seeking care in those aged 20-59; while for those 
aged 60 and older, it was the leading cause (Ministerio de Salud, 2010). 
 
Hypertension Classification and Control 
There are two main hypertension classifications: the European Society of 
Hypertension/European Society of Cardiology (ESH/ESC) classification (Mancia et al., 
2007), and the Seventh Report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure of the National Heart, 
Lung, and Blood Institute (JNC 7 Report) classification (Chobanian et al., 2003). 
Both are based on at least two blood pressure measurements using a sphygmomanometer, 
recording as systolic blood pressure phase I Korotkoff sounds, and as diastolic blood 
pressure phase V Korotkoff sounds (Chobanian et al., 2003; Mancia et al., 2007). Both 
classifications use >140/90 mmHg as the cut point to diagnose hypertension.  
According to the WHO, approximately one billion persons are living with 
uncontrolled hypertension worldwide (Mendis, Puska, & Norrving, 2011). In the United 
States, the prevalence of uncontrolled hypertension is estimated to be 53.5% of those 
with hypertension, affecting approximately 35.8 million persons (Centers for Disease 
Control and Prevention [CDC], 2012a). In a recent study in middle income countries it 
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was found that approximately 33.3% of hypertensive patients were uncontrolled (Basu & 
Millett, 2013). In Panama among hypertensive patients who receive medication, the rate  
of uncontrolled hypertension was 47.2% (McDonald et al., 2012). 
 
Benefits in Controlling Hypertension 
 Several studies had shown the relationship between blood pressure and the risk of 
a cardiovascular event. As was stated by Chobanian et al. (2003), for each increase of 20 
mmHg in systolic blood pressure and 10 mmHg in diastolic blood pressure the risk of 
ischemic heart disease and stroke is doubled. In the same report it was also established 
that the relationship between blood pressure and risk of cardiovascular disease (heart 
attack, heart failure, stroke, and kidney diseases) is continuous, consistent and 
independent of other risk factors, such as high cholesterol, low levels of high-density 
lipoprotein, smoking, diabetes and left ventricular hypertrophy. 
 The benefits of blood pressure level reduction were demonstrated in the VALUE 
study (Weber et al., 2004), in which a lower incidence of cardiovascular disease and 
mortality was observed in those with controlled hypertension compared to those with 
uncontrolled hypertension (blood pressure >140/90mmHg). In addition, in the FEVER 
study (Liu et al., 2005) a 28% reduction in coronary disease, stroke and cardiovascular 
mortality was demonstrated in those randomized to active antihypertensive treatment, 
compared to those randomized to placebo. 
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Improving Hypertension Control 
Hypertension control is a complex issue which, to be achieve, needs active 
cooperation between physicians, patients, healthcare personnel and healthcare systems 
(Chobanian et al., 2003; Mancia et al., 2007). The fist step to address the uncontrolled 
hypertension problem is to develop local comprehensive hypertension prevention and 
treatment guidelines based in well-designed studies. However, these guidelines need to 
be accepted by all medical societies to facilitate their implementation. Medical doctors 
need to be informed about guidelines recommendations but also is necessary an audit 
process that could assess the implementation phase appropriately (Mancia et al., 2007). 
Patient treatment compliance is a complicated problem that is influenced by factors such 
as cultural behaviors and beliefs, and previous experiences in the healthcare systems 
(Chobanian et al., 2003). The healthcare system plays a central role in the hypertension 
control, and is the responsible to provide the necessary tools and audit to guarantee the 
correct guidelines implementation (Mancia et al., 2007). 
The Panamanian national health authorities (Ministry of Health and the Social 
Security Fund), to tackle the hypertension problem developed a structured program to 
address hypertension in cooperation with the Pan American Health Organization in 2009 
(Organización Panamericana de la Salud, 2009). This is a comprehensive program which 
encompass several aspects in hypertension prevention and treatment, however there are 
scarce published data regarding the status of patients treated in primary healthcare 
settings in Panama. 
This study aims to provide information about the feasibility to conduct a larger 
study, and to describe and analyze selected aspects of the hypertensive population. 
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CHAPTER TWO: RESEARCH OBJECTIVES 
 
Objectives 
This study was designed as a feasibility study to assess the current treatment 
practices and to describe select demographic and clinical characteristics of hypertensive 
adults attending the primary healthcare center Luis H. Moreno in Panama City, Republic 
of Panama. 
 The main research question was whether physician adherence to antihypertensive 
protocol recommendations would be associated with patient’s blood pressure control 
status. 
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CHAPTER THREE: METHODOLOGY 
 
Study Design 
This is a cross-sectional study of adult hypertensive patients who attended a 
primary healthcare facility in Panama City, Republic of Panama and received treatment 
for hypertension during the year 2012. Clinical charts from eligible participants were 
examined to describe the demographic and clinical characteristics related to uncontrolled 
hypertension and physician’s adherence to antihypertensive protocols. Descriptive and 
central tendency statistics were used to characterize the study population.  Bivariate 
relationships between demographic and clinical characteristics, and uncontrolled 
hypertension were explored using the chi-square or the Fisher’s exact test for categorical 
distributions, the t-test for parametric continuous distributions, and the Wilcoxon sum-
rank test for non-parametric continuous distributions. Finally, logistic regression 
modeling was used to examine the association between the physician’s adherence to 
antihypertensive protocols and uncontrolled hypertension after adjusting for other factors. 
Prior to data collection, approvals from the University of South Florida’s Institutional 
Review Board (IRB) and from the authorized Panamanian IRB (Punta Pacifica Hospital’s 
IRB) were obtained. 
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Eligibility Criteria 
Eligible subjects were all adult patients (>18 years old), who were treated in 
the center between January 1st, 2012 and December 31, 2012 and had a diagnosis of 
primary hypertension (WHO, 2010). Patients with a diagnosis of primary 
hypertension made during the year 2009 or later, and those initially diagnosed before 
2009 who had not taken hypertensive medication for at least 6 months and re-entered 
treatment in 2009 or later; were included in the study. 
Criteria for exclusion included clinical charts with missing information on the 
appointment at which the antihypertensive pharmacological treatment was initiated, and 
those for which inadequate information was available to establish whether appropriate 
treatment was received and whether blood pressure control was obtained. Additional 
exclusion criteria included patients who had kept regular hypertension control 
appointments for less than six months, and pregnant women (since the treatment and 
classification of hypertensive pregnancy disease is different from primary hypertension) 
(Mancia et al., 2007). 
 
Study Sample and Sample Selection 
The needed sample size to develop the study was obtained using the formula 
developed by Cochran (1963) for proportions in large populations: 
n = [Z^2 P(1-P)]/d^2 → n ≈ 383 participants 
Where: n = sample size; Z = Z statistics for the level of confidence of 95% 
(1.96 for two tailed test); P = Prevalence of uncontrolled 
hypertension in Panama (0.472); d = Precision (0.05). 
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For the sample size calculation, the prevalence of uncontrolled hypertension was 
obtained from a previous study (McDonald et al., 2012) that found that 47.2% of 
hypertensive patients receiving treatment did not achieve blood pressure goals. 
A simple random sample of 383 clinical charts were selected for review, from 
the existing electronic log of all patients who attended the study center between January 
1, 2012 and December 31, 2012 with a diagnosis of primary hypertension (WHO, 2010). 
Demographic data collected included age and gender.  Race/ethnicity was not 
available in the charts and could not be collected. The clinical data that were 
collected included: date at which the pharmacological treatment was initiated 
(hereafter “treatment appointment”), date of follow-up (hereafter “follow-up 
appointment”), height (meters) and weight (kilograms) at the first appointment, 
blood pressure from the first and second appointments, presence of comorbidities, 
prescribed antihypertensive medication, type of attending physician (general 
practitioner and specialist), and if any recommendation of lifestyle modification was 
made during the treatment appointment (Appendix A). The clinical chart of each 
patient was reviewed, and those that met the additional eligibility criteria (diagnosis in 
2009 or later, and those with a diagnosis prior to 2009 with at least 6 months of no 
antihypertensive therapy who had re-entered treatment in 2009 or later) were included in 
the study. Of the 383 clinical charts that were examined, only 117 clinical charts met the 
eligibility criteria for inclusion in the study.  
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Operational Definition of Variables 
Demographic Variables. Age: the age of the patient at the treatment 
appointment, calculated based on the date of birth and date of the treatment 
appointment. 
Gender: Female or male, as recorded in the clinical chart. 
 
Clinical Variables. Treatment Appointment:  the appointment at which the 
antihypertensive pharmacological treatment was initiated, or was re-initiated for 
those previously receiving treatment. 
Follow-up Appointment: the appointment recorded as the hypertension 
follow-up appointment or the appointment in which the first antihypertensive 
medication refill was made, whichever occurred first. 
Height and Weight: the height (meters) and weight (kilograms) to calculate 
the body mass index (BMI) category [CDC], 2012b). 
Blood Pressure: systolic and diastolic blood pressure as recorded by the 
attending physician at both the treatment and follow-up appointments. 
Presence of Comorbidities: the comorbidities noted in the chart at the 
treatment appointment that are listed in the Pan American Health Organization 
Guidelines (PAHO; Organización Panamericana de la Salud, 2009) as comorbidities 
to be considered in the protocol for hypertension treatment (Appendix B). 
Lifestyle Modifications: recorded as “Yes” if there were any notes in the 
clinical chart regarding recommendations following the PAHO Guidelines for 
lifestyle modifications during the treatment appointment. 
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Antihypertensive Medication: all antihypertensive medications prescribed at 
the treatment appointment. 
Type of Physician: the specialty of the attending physician: general 
practitioner or specialist. 
 
Assessment of Treatment Compliance with Antihypertensive Protocols 	   In 2009, the Pan American Health Organization (PAHO), in cooperation with 
the Panamanian health authorities (Ministry of Health and the Social Security Fund), 
issued the Comprehensive Guidelines for the Hypertensive Population Treatment 
(PAHO Guidelines; Organización Panamericana de la Salud, 2009).  This report 
established the procedures for prevention, detection, diagnosis and treatment of high 
blood pressure within the country. These guidelines were used to assess adherence to 
treatment protocols by attending physician. 
The guidelines state that the antihypertensive treatment should consist of both 
lifestyle modifications and pharmacological treatment. These two variables were 
used together to establish physician’s adherence to antihypertensive protocols, as 
described in the two following sections. 
Assessment of lifestyle modification recommendations. The lifestyle 
modification variable was recorded as “Yes” if there was a note recommending any of the 
suggested lifestyle modifications listed in the PAHO Guidelines for the non-
pharmacological treatment of hypertension. The lifestyle modifications considered were: 
physical activity, stress reduction, tobacco cessation, limiting of alcohol use, weight 
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control, reducing sources of sodium, cholesterol and triglycerides in the diet, and 
adequate rest (six to eight hours daily). 
Assessment of pharmacological treatment adherence with antihypertensive 
protocols. From clinical data abstracted in the treatment appointment, patients were 
classified based on the categories of the Seventh Report of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure (JNC 7 Report) of the National Heart, Lung, and Blood Institute (Chobanian 
et al., 2003).  
The pharmacological treatment was determined by the blood pressure level 
during the first appointment. If the blood pressure measure was greater than or equal 
to 140/90 mmHg, the initiation of pharmacological treatment was indicated. If the 
blood pressure level was less than 140/90mmHg, the pharmacological treatment was 
indicated only if diabetes mellitus, cardiovascular disease, or renal disease were 
present as comorbidities (Organización Panamericana de la Salud, 2009). The PAHO 
Guidelines explicitly list diabetes mellitus and renal disease as independent 
cardiovascular disease risk factors. 
Pharmacological treatment adherence with antihypertensive protocols by 
physicians was assessed at the treatment appointment in the following manner: 
patients were classified as “Yes” (appropriately treated) or “No” (inappropriately 
treated) according to the prescribed antihypertensive medication, and listed 
comorbidities (Appendix B). For example, if a patient with hypertension and no 
associated comorbidities was treated with a β - blocker, angiotensin-converting 
enzyme inhibitor (ACEI), angiotensin-receptor blocker (ARB) or calcium-channel 
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blocker (CCB), either alone or in combination (up to 2 agents) then he/she was 
classified as treated appropriately.  If this treatment was not prescribed, then he/she 
was classified as inappropriately treated.  
Finally, if a patient received both lifestyle modifications recommendations 
and received pharmacological treatment following antihypertensive protocols, the 
variable “treatment adherence to antihypertensive protocols” was classified as “Yes” 
(Table 3.1).  If either of the two variables were classified as “No”, the variable 
“treatment adherence to antihypertensive protocols” was classified as “No”.	  
Assessment of Blood Pressure Control Status 
The follow-up appointment was used to assess if the patient reached their 
blood pressure goal, as specified in Table 3.2. To fully consider the impact of 
comorbidities, the goal blood pressure level recommendations from the PAHO 
Guidelines and from the JNC 7 Report were used. Finally, for the remaining patient 
categories, a blood pressure goal level of <140/90 mmHg was used, based on a 
previous study in Panama in which the prevalence of uncontrolled hypertension was 
estimated (McDonald et al., 2012). 
Table 3.1 
 
Assessment of Treatment Compliance with Antihypertensive 
Protocols 
Lifestyle 
Modifications 
Pharmacological 
Treatment 
Treatment 
Adherence 
Yes Yes Yes 
Yes No No 
No Yes No 
No No No 
Note. The variable Treatment Adherence is a combination of the 
variables Lifestyle Modifications and Pharmacological Treatment. 
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Data Collection Procedures 
Once the 383 participants were identified, the clinical record identification 
number (CRIN) was collected and a study identification number (Study_ID) was 
assigned to each clinical chart.  The study identification number went from 001 to 
383.  This code was stored in electronic format, encrypted using the encryption 
software Mac OS X version 10.8.3, and password-protected on the principal 
investigator’s personal computer. Only the principal investigator has access to this 
file and to the personal computer where it is stored.  No other identifier was 
collected, such as name, personal identification number, social security number 
and/or participant's home address. 
Table 3.2 
 
Pressure Level Goals According to Treatment Category 
Category Blood Pressure Goals Basis 
HT alone, Stage 1 or 2a <140/90 JNC 7 Reporta 
HT + Late adulthood (>55 years 
old)b <140/90 
PAHO Guidelinesb 
JNC 7 Reporta 
HT + African American  <140/90 Gorgas Studyc 
HT + DM <130/80 PAHO Guidelinesb 
HT + Chronic Kidney Disease <130/80 PAHO Guidelinesb 
HT + DM + Nephropathy <130/80 PAHO Guidelinesb 
HT + Coronary Heart Disease <140/90 JNC 7 Reporta 
HT + Heart Failure <140/90 JNC 7 Reporta 
HT + LVH <140/90 Gorgas Studyc 
HT + Obesity <140/90 Gorgas Studyc 
HT + Dyslipidemia <140/90 Gorgas Studyc 
HT + Asthma <140/90 Gorgas Studyc 
Note. HT = Hypertension; DM = diabetes mellitus; LVH = left ventricular hypertrophy; JNC = 
Joint National Committee; PAHO = Pan American Health Organization. aAs defined in “The 
seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure: The JNC Report,” by A. V. Chobanian et al., 2003, The 
Journal of the American Medical Association, 289(19), 2560-2572. bAs defined in ¨Guías para la 
atención integral de las personas con hipertensión arterial [Comprehensive guidelines for the 
treatment of hypertensive patients],¨ by Organización Panamericana de la Salud [Pan American 
Health Organization], 2009. Republic of Panama. cAs defined in “Prevalencia de factores de 
riesgo asociados a Enfermedad Cardiovascular [Prevalence of cardiovascular disease risk 
factors],” by Mc Donald et al., 2012. Republic of Panama. 
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An electronic data entry form was developed in Microsoft® 2012 Excel Software 
to capture the study variables (Appendix A) directly from the clinical chart, without any 
paper-based abstraction materials.  The data collection was conducted by the principal 
investigator.  Within the clinical chart, the demographic variables were abstracted from 
the “Demographic Information Section” and the clinical variables from the “Medical 
Information and Follow-up Section.”  Then, when all data were collected, they were 
imported to Statistical Analysis System Software (SAS) Version 9.2 and to IBM SPSS 
Statistics Software for the analysis. 
In order to test reliability and assure the quality of the data, re-abstraction of 
approximately 20% of the sample was performed.  The following variables were 
abstracted: date of birth, age, systolic and diastolic blood pressures during the first and 
second appointments, lifestyle modification recommendations during first appointment, 
medications prescribed in the first appointment and existing comorbidities.  
Race/ethnicity was not referenced in the clinical chart and therefore, could not be 
abstracted.  A research assistant did the re-abstraction and these data were compared with 
the data collected by the principal investigator using the same clinical charts.  To assess 
the level of agreement between the two abstractors, a kappa statistic was used for 
categorical variables and the intraclass correlation coefficient for continuous variables.  
The kappa coefficient ranged from 0.854 to 1.000 and the intraclass correlation 
coefficient ranged from 0.940 to 0.996, showing very good to excellent agreement 
between abstractors (Byrt, 1996).  
When all data analysis is completed, all files generated will be moved to an 
external storage drive (flash drive) and deleted from the principal investigator’s 
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personal computer.  The external storage disk will be stored and locked in the 
facilities of the University of South Florida at the City of Knowledge in Panama, 
where it will remain for five years. After five years, the disk will be destroyed using 
the services of a certified company. The principal investigator will attend the disc 
destruction and receive a certificate that guarantees that the full process was 
executed. 
 
Statistical Analysis 
In the univariate analysis, for continuous variables Q-Q plots were used to assess 
if the variable was normally distributed. For those variables which were normally 
distributed, the mean and standard deviation were used as descriptive statistics; and for 
those that were not normally distributed the median and interquartile range (IQR) were 
used.  For categorical variables, the results were presented as frequencies and 
proportions.  
A bivariate analysis was performed to compare demographic and clinical 
variables with the dependent variable “Blood Pressure Control Status (Uncontrolled, 
Controlled)”. An independent sample t test was used for continuous normally distributed 
variables, Wilcoxon Sum-Rank test for continuous non-normally distributed variables, 
and Fisher’s exact test or chi-squared test for categorical variables, depending if the 
observed frequencies in any cell was less than five or not. To assess if the change in the 
blood pressure between both treatment and follow-up appointment was significant, a pair 
t test was performed. For all comparisons an alpha of 0.05 was used as level of statistical 
significance.  
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Finally, to investigate the relationship between the physician’s adherence to 
antihypertensive protocols and the presence of uncontrolled hypertension among 
participants, controlling for other covariates, a multivariate analysis was performed using 
a logistic regression model.   
Covariates were included in the model, in the following order; first, those 
variables that had a statistical significant relationship with the dependent variable in the 
bivariate analysis: age, number of comorbidities, and the presence of diabetes mellitus. 
Second, the variables gender and type of attending physician were forced to be in the 
model, based in the association showed in previous studies (CDC, 2012a; Egan, Zhao, 
Axon, Brzezinski, & Ferdinand, 2011; Basu & Millett, 2013; Kim et al., 2007; Amar et 
al., 2003). Third, those variables considered to be potential confounding variables were 
included in the model; being those that provoked a change in the measure of association 
(odds ratio, OR) between the dependent and independent variable in more than 10% 
(ΔOR>10%). 
To determine the presence of effect modification, interactions were tested 
between the main effect variable and the covariates included in the model. If an 
interaction was observed, stratified models based on the levels of the potential modifier 
would be developed, to unveil the association by each stratum. 
Finally, to test whether or not our final model provides a good fit to the data, a 
Goodness-of-Fit Test was performed. 
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CHAPTER FOUR: RESULTS 
 
Univariate Analysis – Patients Characteristics  
Demographic Variables. Table 4.1 shows the study sample baseline 
characteristics. The participant’s mean age was 56.7 years (±13.6). From the total of 
participants, 58.1% (n=68) were females and 41.9% (n=49) were males.  
Clinical Variables. For body mass index (BMI), 40.6% (n=41) were obese, 
30.7% (n=31) were overweight, 26.7% (n=27) were at healthy weight, and 2.0% (n=2) 
were underweight. There were 16 observations with missing values to calculate the BMI. 
For hypertension classification, 53.0% (n=62) of participants were at Stage 2, 43.6% 
(n=51) were at Stage 1 and 3.4% (n=4) were Prehypertensive.  During the first 
appointment, the mean systolic blood pressure (SBP) was 150.0 mmHg (±14.7), while the 
mean diastolic blood pressure (DBP) was 92.3 mmHg (±9.4).  In the second appointment, 
the mean SBP was 135.6 mmHg (±18.6) and the mean DBP was 84.7 mmHg (±10.7). 
Systolic and diastolic blood pressure significantly decreased between the treatment and 
follow-up appointments (14.44 mmHg ±19.3 and 7.60 mmHg ±12.51, respectively; 
p<0.0001 for both). For the number of comorbidities, 17.1% (n=20) had zero 
comorbidities, 47.0% (n=55) had one comorbidity, 27.4% (n=32) had two comorbidities, 
7.7% (n=9) had three and 0.8% (n=1) had one comorbidity. In this study sample, 28.2% 
(n=33) had diabetes mellitus, while 71.8% did not. General practitioners attended 62.4% 
(n=73) of participants, while 37.6% (n=44) were attended by a specialized medical  
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Table 4.1 
 
Baseline Characteristics of Study Population 
Characteristic  
Age, years; Mean (±SD) 56.7 (±13.6) 
Gender; n (%)  
Female 68 (58.1) 
Male 49 (41.9) 
Body Mass Index; n (%) 
Underweight (<18.5 kg/m2) 2 (2.0) 
Healthy Weight (18.5 - <25.0 kg/m2) 27 (26.7) 
Overweight (25.0 – 30.0 kg/m2) 31 (30.7) 
Obese (≥30.0 kg/m2) 41 (40.6) 
Hypertension Classification, JNC 7 Stagea; n (%) 
Pre Hypertension 4 (3.4) 
Stage 1 51 (43.6) 
Stage 2 62 (53.0) 
Treatment App SBP, mmHg; Mean (SD) 150.0 (±14.7) 
Treatment App DBP, mmHg; Mean (SD) 92.3 (±9.4) 
Follow-up App SBP, mmHg; Mean (SD) 135.6 (±18.6) 
Follow-up App DBP, mmHg; Mean (SD) 84.7 (±10.7) 
SBP Mean Change, mmHg; Change (SD)* 14.4 (±19.3) 
DBP Mean Change, mmHg; Change (SD)* 7.6 (±12.5) 
Number of Comorbidities; n (%)  
0 20 (17.1) 
1 55 (47.0) 
2 32 (27.4) 
3 9 (7.7) 
4 1 (0.8) 
Diabetes Mellitus among comorbidities; n (%) 
Yes 33 (28.2) 
No 84 (71.8) 
Attending physician; n (%)  
General Practitioner 73 (62.4) 
Specialist 44 (37.6) 
Blood Pressure Status; n (%) 
Uncontrolled 78 (66.7) 
Controlled 39 (33.3) 
  
Note. SD = standard deviation; n = number of subjects; JNC = Joint National 
Committee; App, appointment; SBP, systolic blood pressure; DBP, diastolic blood 
pressure. For continuous and normally distributed variables the mean was used as 
central tendency measure. *A pair t-test was used to assess the change in systolic and 
diastolic blood pressure change; in both cases p<0.0001.aAs defined in “The seventh 
report of the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure: The JNC Report,” by A. V. Chobanian et al, 2003, 
The Journal of the American Medical Association, 289(19), 2560-2572. 
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doctor. The majority, 66.7% (n=78), had uncontrolled high blood pressure, while 33.3% 
(n=39) had their blood pressure below goal levels. 
 Table 4.2 presents the treatment characteristics of the participants. Regarding the 
number of antihypertensive medication, 76.1% (n=89) of cases were prescribed with one 
medication, 23.1% (n=27) of cases were prescribed two antihypertensive medications and 
0.8% (n=1) was prescribed with three medications. Lifestyle modification 
recommendations were given to 43.6% (n=51) of participants, while they weren’t given 
to 56.4% (n=66). The majority of physicians adhered to the pharmacological 
antihypertensive treatment protocols (98.3%; n=115), while in just 1.7% (n=2) the 
protocols were not followed. Combining the lifestyle modification recommendations and 
pharmacological antihypertensive treatment to assess compliance with the 
antihypertensive protocols, 43.6% (n=51) of participants received treatment following the 
PAHO Guidelines, while 56.4% (n=66) did not.  The median of treatment days was 31 
(IQR=10.50-69.50) in the study sample. 
Table 4.2 
 
Treatment Characteristics of Study Population 
Characteristic 
Number of Antihypertensive medication(s) prescribed; n (%) 
1 89 (76.1) 
2 27 (23.1) 
3 1 (0.8) 
Treatment days; Median (IQR) 31 (10.5-69.5) 
Lifestyle Modifications recommended; n (%) 
Yes 51 (43.6) 
No 66 (56.4) 
Antihypertensive medication(s) following protocols; n (%) 
Yes  115 (98.3) 
No 2 (1.7) 
Treatment compliance with antihypertensive protocols; n (%) 
Yes 51 (43.6) 
No 66 (56.4) 
Note. n = number of subjects; IQR, interquartile range. For continuous and non-
normally distributed variables the median was used as central tendency measure. 
	   20 
Bivariate Analysis 
Demographic Variables. Table 4.3 presents the results of the bivariate analyses 
between the demographic and clinical characteristics, and blood pressure control status. 
Those with uncontrolled hypertension were older (58.6 years, ±14.2) than those with 
uncontrolled hypertension (53.1 years, ±11.7; p<0.0396). Among those with uncontrolled 
hypertension 53.9% were females, compared to those who were controlled (66.7%).  
However, this difference was not statistically significant (p=0.1852). 
There was a higher proportion of overweight participants in the uncontrolled 
group (34.8%) compared to the controlled group (22.8%). However, a higher proportion 
of the controlled group (48.6%) than the uncontrolled group (36.4%) were classified as 
obese.  Nevertheless, the difference between groups was not statistically significant 
(p=0.3845). 
  Clinical Variables. In the uncontrolled group a higher proportion of participants 
were at stage 2 hypertension (56.4%) than in the controlled group (46.2%).  However, it 
was the opposite for stage 1 hypertension, which was less prevalent in the uncontrolled 
group (41.0%) than in the controlled group (48.7%).  But, the differences found between 
these groups were not significant ((p=0.5202). 
During the first appointment, the mean systolic blood pressure for the 
uncontrolled group was 151.2 mmHg (±15.7) and for the controlled group was 147.7 
mmHg (±12.3), with no statistical relationship with the dependent variable (p=0.2234).  
At the same appointment, the mean diastolic blood pressure for the uncontrolled group 
was 92.4 mmHg (±9.7) and for the controlled group was 92.1 mmHg (±8.8), with no  
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Table 4.3 
 
Patients Characteristics by Blood Pressure Control Status 
Characteristic Uncontrolled Controlled p-value* 
Blood Pressure Status; n (%) 78 (66.7) 39 (33.3) NA 
Age, years; Mean (SD) 58.6 (14.2) 53.1 (11.7) 0.0396 
Gender; n (%)    
Malea 36 (46.1) 13 (33.3) 0.1852 Female 42 (53.9) 26 (66.7) 
Body Mass Indexb; n (%)    
Healthy Weighta (<25.0 kg/m2) 19 (28.8) 10 (28.6) 
0.3845c Overweight (25.0 - <30.0 kg/m2) 23 (34.8) 8 (22.8) 
Obese (≥30.0 kg/m2) 24 (36.4) 17 (48.6) 
JNC 7 Staged; n (%)    
Pre Hypertensiona  2 (2.6) 2 (5.1) 
0.5202 Stage 1 32 (41.0) 19 (48.7) 
Stage 2 44 (56.4) 18 (46.2) 
Tx App SBP, mmHg; Mean (SD) 151.2 (15.7) 147.7 (12.3) 0.2234 
Tx App DBP, mmHg; Mean (SD) 92.4 (9.7) 92.1 (8.8) 0.8685 
SBP Changee, mmHg; Change (SD) 8.5 (±18.4) 26.4 (±16.4) <.0001 
DBP Changee, mmHg; Change (SD) 3.6 (±10.5) 15.5 (±6.7) <.0001 
Number of Comorbidities; n (%)    
0a 12 (15.4) 8 (20.5) 
0.0488 1 32 (41.0) 23 (59.0) 
≥2 34 (43.6) 8 (20.5) 
Diabetes Mellitus among comorbidities; n (%)  
Noa 50 (64.1) 34 (87.2) 0.0089 Yes 28 (35.9) 5 (12.8) 
First App Antihypertensive medication(s) prescribedf; n (%)  
1a 58 (74.4) 31 (79.5) 0.5400 ≥2 20 (25.6) 8 (20.5) 
Attending physician; n (%)    
Specialista 31 (39.7) 13 (33.3) 0.4998 General Practitioner 47 (60.3) 26 (66.7) 
Treatment compliance with antihypertensive protocols; n (%)  
Noa 43 (55.1) 23 (59.0) 0.6925 Yes 35 (44.9) 16 (41.0) 
Treatment days; Median (IQR) 30.5 (10.0-56.3) 33 (14.0-90. 0) 0.4250 
Note. n = number of subjects; NA = do not apply; SD = standard deviation; Ref = reference group; 
JNC = Joint National Committee; Tx = Treatment;App = appointment; SBP = systolic blood 
pressure; DBP = diastolic blood pressure; IQR = interquartile range. P-values were obtained by 
using the t-test for continuous variables, the chi-square test for categorical variables and pait t-test 
for pair data. *p<.05. aReference group.  bThe body mass index categories Healthy Weight (n=27) 
and Underweight (n=2) were collapsed in the category Healthy Weight. cMissing data not included 
in the analysis (n=16). dAs defined in “The seventh report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC Report,” by A. 
V. Chobanian et al, 2003, The Journal of the American Medical Association, 289(19), 2560-2572. 
eMean change. fThe antihypertensive medication categories “2” (n=27) and “3” (n=1) were 
collapsed in category “2”. 
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statistical relationship with the dependent variable (p=0.8685). The reductions in systolic 
and diastolic blood pressure were significantly higher in the control group than in the 
uncontrolled group (in both cases p<0.0001). 
 A larger percentage of participants in the uncontrolled group (43.6%) had two or 
more comorbidities, compared to those in the controlled group (20.5%). The differences 
found between groups in the number of comorbidities were statistically significant 
(p=0.0488).  The categories “two comorbidities”, “three comorbidities” and “four 
comorbidities” were merged due to low frequencies (n=9 and n=1, respectively).   
Diabetes mellitus, as a comorbidity, was observed more frequently in the 
uncontrolled group (35.9%) than in the control group (12.8%, p=0.0089). There was no 
difference in the proportions prescribed with two or more antihypertensive medication in 
the uncontrolled group (25.6%) compared to those in the controlled group (20.5%, 
p=0.5400). The percentage of participants attended by a general practitioner in the 
uncontrolled group (60.3%) was not different compared to the controlled group (66.7%, 
p=0.4998). 
The percentage of medical doctors that followed the recommendations of the 
antihypertensive protocols was 44.9% for the uncontrolled group, compared to the 
controlled group (41.0%).  However, the differences were not significant (p=0.4998). 
Finally, the number of antihypertensive treatment days did not differ for the 
uncontrolled group (30.5 days, Interquartile range [IQR]: 10.0-56.3), compared to the 
controlled group (33.0 days, IQR=14.0-90.0; p=0.4250).  
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Multivariate Analysis 
` Table 4.4 presents the crude and adjusted odds ratio estimates for physician 
adherence to antihypertensive protocols and the demographic and clinical characteristics 
of the subjects. Physician adherence to antihypertensive protocols was not significantly 
associated with blood pressure control status in either the crude or adjusted models. 
 To determine the presence of effect modification, interactions were tested 
between the main effect variable (physician adherence to antihypertensive protocols by 
medical doctors) and the covariates included in the model. Table 4.5 presents the p-
values for the interaction terms. A significant interaction was found with age (p=0.0454). 
Table 4.4 
 
Crude and Adjusted Odds Ratios for Physician Adherence to Antihypertensive 
Protocols and Covariates 
Variable Crude Model OR (95% CI) 
Adjusted Model 
OR (95% CI) 
Physician Adherence 
 Ref = No 1.17 (0.54-2.55) 1.31 (0.48-3.564) 
Age 1.03 (1.00-1.06) 1.05 (0.99-1.10) 
Diabetes Mellitus 
 Ref = No 3.81 (1.34-10.84) 2.90 (0.58-14.46) 
Gender 
 Ref = Male 0.58 (0.26-1.30) 0.649 (0.25-1.70) 
Attending Physician 
 Ref = No 0.76 (0.34-1.70) 1.89 (0.54-6.62) 
Number of Comorbidities 
 1 vs 0 
 Ref = Zero 
0.93 (0.34-2.63) 0.76 (0.17-3.50) 
Number of Comorbidities 
 2 vs 0 
 Ref = Zero 
2.83 (0.87-9.23) 1.20 (0.16-8.93) 
Body mass index 
 Obese vs Healthy Weight 0.74 (0.28-2.00) 1.46 (0.31-6.87) 
Body mass index 
 Overweight vs Healthy 
Weight 
1.51 (0.50-4.60) 2.03 (0.56-7.37) 
Note. OR = odds ratio; CI = confidence interval; Ref = reference group. 
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There were no significant differences by levels of the number of comorbidities 
(p=0.6539), diabetes mellitus (p=0.7194), gender (p=0.3941), and type of  
attending physician (p=0.7286). For body mass index, the interaction was dropped from 
the final model, because the point estimate was not estimable for the main effect variable 
due to low numbers in the healthy weight category. 
Stratified models were run for the potential effect modifier “age”, using a cut 
point at the mean age (56.7 years); one model for those below or equal to the mean, and 
Table 4.5  
 
Interaction Terms with Variables Included in the Model 
Variable p-value* 
Age 0.0454 
Diabetes Mellitus 0.7194 
Gender 0.3941 
Attending Physician 0.7286 
Number of Comorbidities 0.7883 
Body mass index 0.0311 
*p<.05. 
Table 4.6 
 
Stratified Models by Age as a Potential Modifier 
Age ≤ 56.7 years OR (95% CI) 
Physician Adherence 
 Ref = No 0.85 (0.22-3.22) 
Gender 
 Ref = Male 0.85 (0.29-2.51) 
Attending Physician 
 Ref = No 0.73 (0.18-2.97) 
Age > 56.7 years OR (95% CI) 
Physician Adherence 
 Ref = No 1.61 (0.35-7.34) 
Gender 
 Ref = Male 0.19 (0.03-1.04) 
Attending Physician 
 Ref = No 1.31 (0.28-6.10) 
Note. OR = odds ratio; CI = confidence interval; Ref = reference 
group. 
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one model for those above the mean. Inestimable parameters were found for the variables 
number of comorbidities, the presence of diabetes mellitus and BMI; therefore, these 
variables were dropped from the models; and the models were run again. 
In Table 4.6 are shown the results for the models stratified by age. From these 
models it can be observed that the estimates were different for the levels of age. These 
findings suggest that age is a potential effect modifier for the association between 
uncontrolled hypertension and the physician’s adherence to antihypertensive protocols. 
The Hosmer-Lemeshow Goodness-of-Fit test indicated a good model fit 
(p=0.5717). 
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CHAPTER FIVE: DISCUSSION 
 
Key Findings 
The aim of this study was to describe the characteristics of uncontrolled 
hypertension in a primary healthcare center and the factors associated with this condition.  
This study was designed as a feasibility study to assess the current treatment 
practices for hypertensive adults. One of the critical findings of this study is that 66.7% 
of the study sample had uncontrolled hypertension, a result that differs from another 
study in Panama in which the prevalence of uncontrolled hypertension was 47.2% 
(McDonald et al., 2012). However, this results was not unexpected considering that our 
study was clinically based at a primary healthcare center serving a single county of the 
Panama province, the target population was the hypertensive adult population visiting the 
clinic, and, finally, the study used a more conservative blood pressure cut point to define 
uncontrolled hypertension (>130/80 mmHg, or >140/90 mmHg, depending on the type of 
comorbidities). The Gorgas study was population based, with a target population of the 
general adult population (hypertensive and non-hypertensive adults) in the two main 
Panama provinces (in which the 57.4% of the total Panamanian population reside), and 
defined uncontrolled hypertension using a more liberal cut point (>140/90 mmHg for all 
hypertensive population, regardless the type of comorbidities).  
A logistic regression model was used to investigate the relationship between 
physician adherence to antihypertensive protocols and the presence of uncontrolled 
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hypertension. A significant interaction term was found between physician adherence to 
protocols and age. In the stratified models, the odds ratios for physician adherence to 
protocols were in opposite directions, although the estimates were not significantly 
different from one. These results suggest that age could be a potential effect modifier for 
the association between physician adherence to antihypertensive protocols and the 
presence of uncontrolled hypertension. However, due to the small sample size, the 
possible role of age as an effect modifier for the mentioned the relationship needs further 
examination. 
There is a potential biologic explanation for these findings. A study derived from 
the Framingham cohort, showed that systolic blood pressure increased linearly with age 
during lifetime; however, diastolic blood pressure increased linearly until the age of 50 to 
60 years, and after this tended to level off over a decade, and later on may stay the same 
or decrease (Franklin et al., 1997). This phenomenon produces a steep increase, after 50 
to 60 years, in pulse pressure (systolic minus diastolic blood pressure); and became, 
along with systolic blood pressure, potent cardiovascular risk factors in this age group 
(Chobanian et al., 2003; Mancia et al., 2007). However, for those aged <50 years, 
diastolic blood pressure is more important cardiovascular risk factor than systolic blood 
pressure or pulse pressure (Franklin et al, 2001; Chobanian et al., 2003). The joint 
increase of systolic and diastolic blood pressure until the age of 50 years, makes the 
pharmacological titration process easier for physicians since both systolic and diastolic 
blood pressure will be relatively high; however for those above 50 years old, isolated 
systolic hypertension is more expected, and therefore it will be difficult to induce a 
decrease in systolic blood pressure without a decrease in diastolic blood pressure, that 
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could lead to hypotension symptoms; which makes hypertension control in this age group 
more difficult. This is supported by several studies in primary care settings that 
demonstrated that 75% of physicians failed to initiate hypertension treatment in older 
individuals with systolic blood pressure 140 – 159 mmHg and most of them did not chase 
control rates (systolic blood pressure <140 mmHg; Hyman, Pavlik, & Vallbona, 2000; 
Berlowitz et al., 1998). 
 In the bivariate analyses the following variables were associated with having 
uncontrolled hypertension: age, number of comorbidities and the presence of diabetes 
mellitus. However, in the adjusted models these variables were no longer significant. 
Other studies have reported an association between increasing age and 
uncontrolled hypertension (CDC, 2012a; Mejía-Rodríguez et al., 2009); while a recent 
study by Basu and Millett (2013) reported that age was not associated with uncontrolled 
hypertension in middle-income countries. However, the statistically significant 
interaction found in our study (between age and the physician adherence to 
antihypertensive protocols), was not considered in these studies. 
The association found between the number of comorbidities and having 
uncontrolled hypertension is consistent with a previous study that demonstrated similar 
findings (Amar et al, 2003); however, in the previously mentioned study, the risk factors 
considered as comorbidities were not exactly the same than the comorbidities defined in 
the current study. We used the Panamanian Guidelines for the Hypertensive Population 
Treatment (Organización Panamericana de la Salud, 2009) to define these comorbidities, 
so the role of specific comorbidities in the development of uncontrolled hypertension is a 
topic that will prompt more research. 
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For diabetes mellitus, we found that 28.2% of study sample had this condition as a 
comorbidity, in contrast with the 55% reported by a previous study in Panama 
(McDonald, 2012). Diabetes mellitus, as a comorbidity, was associated with having 
uncontrolled hypertension; this finding is consistent with the literature that has 
demonstrated a similar relationship (Amar et al, 2003; Egan et al., 2011; Mejía-
Rodríguez et al., 2009). 
In the bivariate analysis, no associations were found for gender, body mass index, 
hypertension stage (according to the classification of the JNC 7 Report; Chobanian et al, 
2003), systolic and diastolic blood pressure during the treatment appointment, number of 
antihypertensive medications prescribed, type of attending physician, time since 
treatment started, and treatment following protocols recommendations.  However, several 
studies had shown the relationship between these independent variables and having 
uncontrolled hypertension (Egan et al, 2011; CDC, 2012a; Basu & Millett, 2013; Mejía-
Rodríguez, 2009; Kim et al, 2009; Mounier-Vehier, Sanchez-Ponton, Delsart, & 
Miljkovic, 2010; Hyman & Pavlik, 2002).  These results could be a reflection of one of 
the main limitations of this study, the sample size.  
 
Limitations and Strengths  
This study was designed as a feasibility study and it provides some insight on how 
future studies need to be designed; however some important limitations should be 
mentioned.  
The main limitation is the sample size, which was a third of the required number 
(117 out of 383 participants), resulting in a lack of power to detect statistically significant 
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differences. This means that even when there was a difference between those patients that 
were treated following the protocols and those that were not, our study was not able to 
detect a statistically significant difference between these groups. 
These results may not be generalizable to the general population because the 
study center was not chosen by randomization; instead it was selected based on 
accessibility and available permission to perform the study. As the study was based on 
clinical chart review, the diagnosis of hypertension was not independently confirmed.  
Also, data were not collected for some important covariates that have previously 
been shown to have an association with uncontrolled hypertension, such as smoking 
history (Amar et al., 2003; Chmiel et al., 2012), cholesterol levels (Amar et al., 2003), 
renal function (Mounier-Vehier et al., 2010), therapeutic inertia (Egan et al., 2011), 
income (CDC, 2012a; Basu & Millett, 2013), education (Mounier-Vehier et al., 2010) 
and alcohol intake (Mounier-Vehier et al., 2010).  Race/ethnicity was not recorded in the 
clinical chart, and therefore could not be considered in the analysis. Approximately 14% 
of observations were missing height, weight or both to calculate body mass index, and 
were not included in the multivariate analysis. Another limitation was that patient 
compliance with antihypertensive treatment and lifestyle modifications recommendations 
were not assessed. From the mentioned above and the fact that our design does not let us 
to establish temporality, no statements on causality or prevalence of uncontrolled 
hypertension in the general population can be derived.  
 The strengths of this study include that it was designed to minimize sources of 
systematic error. Multivariate logistic regression models were developed to test 
association between physician adherence to protocols and uncontrolled hypertension. 
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Another strength of this study is that a more conservative blood pressure cut point 
(>130/80 mmHg) was used for those with diabetes mellitus or any kind of nephropathy to 
establish the presence of uncontrolled hypertension. Other studies have used a set blood 
pressure cut point of >140/90 mmHg for all subjects. 
 
Conclusions 
 Uncontrolled hypertension is a public health problem worldwide, and the 
population prevalence estimates for Panama is 47.2%. Among this study population the 
prevalence of uncontrolled hypertension was 66.7%, which is reflective of a clinic-based 
population but it cannot be generalized to the general population.  
 Nearly half of the attending physicians did not follow the recommendations given 
by current antihypertensive protocols, primarily due to a lack of recommending lifestyle 
modifications. Physician adherence to pharmacological treatment recommendations was 
high (98.3%). However, it was not possible to demonstrate an association between 
physician adherence to antihypertensive protocols and the presence of uncontrolled 
hypertension, in the multivariate analysis.   
 Further research is necessary to fully assess the association between age, number 
of comorbidities and presence of diabetes mellitus with uncontrolled hypertension; 
specifically to assess the role of age as a potential modifier for the association between 
uncontrolled hypertension and the physician adherence to antihypertensive protocols 
recommendations. Is imperative to know which antihypertensive protocols 
recommendations work for what specific age groups, because specific recommendations 
can be restated to benefit the hypertensive population with poor blood pressure control. 
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 As a feasibility study, this research provides valuable insight in the design and 
direction of future studies. For example, future studies should comprehensively examine 
the role of age in uncontrolled hypertension and as a potential effect modifier of 
physician adherence to protocols. In addition, future studies should adequately control for 
all potential confounders, should be appropriately sized, and should include a measure of 
patient compliance to antihypertensive protocols. 
 
Recommendations 
 Further research needs to be conducted using an adequate sample size to confirm 
the results of this study. In addition, further exploration of the roles of age in uncontrolled 
hypertension is warranted. 
 In Panama, further research in hypertension is necessary to determine the 
population prevalence of uncontrolled hypertension using a blood pressure cut point 
specific for individual comorbidities; as well as, to establish the risk factors associated 
with uncontrolled hypertension. 
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Appendix A: Electronic Data Entry Form 	  
Study Identification Number:   	  
 
Age:  Gender: ☐ Male Race/Ethnicity ☐ Indigenous 
  ☐ Female  ☐ African American 
Height:  Weight:   ☐ Other: 	  	  
Comorbidities:     
 1   4.  
 2.   5.  
 3.   6.  	  
Treatment Appointment  
 
   
Blood Pressure:  Date:   
Lifestyle Modifications? Yes      
No 
 
 
 
Antihypertensive   Dosage  Frequency 
1.     
2.     
	  
Follow-Up Appointment  
 
   
Blood Pressure: 
 
Date: 
 
 
 
Antihypertensive   Dosage  Frequency 
1.     
2.     	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Appendix A: (Continued) 	  
According to the antihypertensive medication given in the first appointment and 
according to the treatment category, was the patient treated according to protocols? 
 ☐ Yes   ☐ No     
 
According to the blood pressure in the second appointment, was the expected 
blood pressure level reached? 
 ☐ Yes   ☐ No     
 
Type of Attending Physician 
 ☐ General Practitioner  ☐ Specialist 
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Appendix B: Classification in Appropriately and Inappropriately Treated 
Hypertension According to the Guidelines of the Pan American Health 
Organization – Republic of Panama 
 
Table B.1 
 
Treatment Classification According to the Guidelines of the Pan American 
Health Organizationa 
Category Appropriately Treated 
HT alone, Stage 1 or 2b 
Treated with a diuretic, β-blocker, ACEI, ARB 
or CCB either alone or in combination (up to 2 
agents) 
HT + Late adulthood  
(>55 years old) 
Treated with a diuretic, β-blocker, ACEI, ARB, 
α-blockers, either alone or in combination 
HT + African American Treated with a diuretic, ACEI, CCB, ARB, α-blockers, either alone or in combination 
HT + Diabetes Mellitus (DM) Treated with a ACEI, ARB, diuretic, CCB, α-blocker, β-blocker either alone or in combination  
HT + Chronic Kidney Disease Treated with a loop diuretic alone or in combination with CCB, ACEI or ARB  
HT + DM + Nephropathy 
Treated with either a ACEI or a ARB alone or in 
combination with CCB’s, diuretics, α-blockers 
or β-blockers 
HT + Coronary Heart Disease Treated with a β-blocker, ACEI, ARB, CCB either alone or in combination 
HT + Heart Failure 
Treated with a ACEI, ARB, β-blocker, diuretics, 
Aldosterone Antagonist, either alone or in 
combination 
HT + Left Ventricular Hypertrophy Treated with ACEI, ARB, diuretics, β-blocker, or CCB, either alone or in combination 
HT + Obesity Treated with a ACEI, ARB, diuretics, β-blocker, or CCB, either alone or in combination 
HT + Dyslipidemia 
Treated with a ACEI, ARB, CCB, thiazide 
diuretic, or β-blocker, either alone or in 
combination 
HT + Asthma 
Treated with any antihypertensive medication, 
either alone or in combination, excluding any β-
blocker (is totally contraindicated)  
Note. DM = diabetes mellitus; ACEI = angiotensin-converting enzyme inhibitor; ARB = 
angiotensin-II-receptor blocker; CCB = calcium channel blocker. aAdapted from “Estimated 
annual direct expenditures in the United States as a result of inappropriate hypertension treatment 
according to national guidelines,” by S. Balu, 2009, Clinical Therapeutics, 31(7), p. 1581-1595. 
bAs defined in “The seventh report of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure: The JNC Report,” by A. V. Chobanian et al, 
2003, The Journal of the American Medical Association, 289(19), 2560-2572. 
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Appendix C: University of South Florida’s Institutional Review Board Letter of 
Approval 	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Appendix C: (Continued) 	  
	  	  
	   43 
Appendix D: University of South Florida’s Institutional Review Board Letter of 
Approval of Amendment 1 	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Appendix E: Panama’s Institutional Review Board Letter of Approval (Spanish) 	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Appendix F: Panama’s Institutional Review Board Letter of Approval (Translation) 	  
	  
